Antibodies have become one of the most important classes of modern therapeutics, with applications spanning cancer, autoimmune disease, infectious disease, and rare genetic disorders. Their ability to recognize targets with high specificity, flagging cells for destruction or for direct treatment, makes them invaluable for treating a variety of ailments spanning cancer, autoimmune disease, infectious disease, and rare genetic disorders.
However, antibody discovery and development are notoriously lengthy and difficult processes that can take anywhere from 10-15 years.1,2 Despite extensive experimentation and therapeutic antibody vetting, approximately 85-90% of drug candidates fail during clinical development, never making it to patients and wasting years of time and money.2
From Target to Candidate
To discover a new antibody, scientists must first identify a disease-relevant protein. Target identification is typically followed by target validation, where researchers confirm that modulating the target is likely to produce a therapeutic benefit. This stage often relies heavily on cell-based models and engineered cell lines that allow scientists to study target biology and disease mechanisms in a controlled environment.1
Researchers then generate large antibody libraries via various approaches including animal immunization, hybridoma technology, phage display, or transgenic mouse platforms, and painstakingly screen millions of candidate antibody sequences for their binding affinity, specificity to a target, and functional activity.
Cell lines play an important role throughout this stage of discovery and are commonly used to express target proteins, support functional screening assays, evaluate antibody activity, and produce early quantities of candidate antibodies for testing. By providing reproducible biological systems, cell lines help researchers compare and prioritize antibody candidates before advancing them into more resource-intensive studies.1
Generative AI and the Road Ahead
Over the past several decades, innovations in screening technologies, cell line engineering, computational modeling, machine learning, and artificial intelligence have helped researchers address many of the major bottlenecks in antibody discovery. Scientists first integrated computational methods into the antibody discovery process decades ago, and machine learning models in the mid-2000s to address several pain points of antibody discovery and accelerate the path to antibody development.1,3 These tools enabled researchers to model antibody structure, binding, and interaction and predict which antibody candidates would have the highest binding affinity for the target and the highest likelihood of preclinical success.3,4
Today’s generative AI technologies build on these early applications but help scientists move beyond simply making predictions about the likelihood of candidate antibody success and move to generating better antibody candidates from the start. These algorithms train on enormous biological datasets to learn patterns within protein sequences, structures, and disease biology, enabling them to make connections between complex biological networks and disease and identify new antibody candidates rather than merely evaluate them for success.3,5
Ultimately, successful antibody discovery relies on the integration of numerous technologies, from cell line engineering and high-throughput screening to computational modeling and artificial intelligence. While each of these tools helps address different challenges in the discovery process, they share a common goal: enabling researchers to identify safer, more effective therapeutic antibodies and bring them to patients more efficiently. As these technologies continue to evolve, they promise to expand the range of diseases that can be treated with antibody-based medicines and improve the likelihood of discovering the next generation of life-changing therapies.
References
1. Norman RA, Ambrosetti F, Bonvin AMJJ, et al. Computational approaches to therapeutic antibody design: established methods and emerging trends. Brief Bioinform. 2020;21(5):1549-1567.
2. Jayatunga MKP, Ayers M, Bruens L, et al. How successful are AI-discovered drugs in clinical trials? A first analysis and emerging lessons. Drug Discovery Today. 2024;29(6):104009.
3. Wossnig L, Furtmann N, Buchanan A, et al. Best practices for machine learning in antibody discovery and development. Drug Discovery Today. 2024;29(7):104025.
4. Waight AB, Prihoda D, Shrestha R, et al. A machine learning strategy for the identification of key in silico descriptors and prediction models for IgG monoclonal antibody developability properties. mAbs. 2023;15(1):2248671.
5. Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873):583-589.